Search
lacosamide (Vimpat, erlosamide, harkoseride)
Indications:
- partial seizures in adults & in children 4 years & older
- primary generalized tonic-clonic seizures n adults & in children 4 years & older [3]
Contraindications:
- avoid in patients with severe liver failure [2]
Dosage:
- oral solution or tablet (children)
- injection (adults only)
Dosage adjustment in renal failure:
- when GFR < 30 mL/min
- supplemental dose after dialysis [2]
Pharmacokinetics:
- combined hepatic/renal elimination [2]
Adverse effects:
- common
- sedation, dizziness, ataxia, diplopia, nausea
- prolonged ECG PR interval [2]
- serious
- arrhythmias (bradyarrhythmia, AV block) [2]
- syncope
- hypersensitivity [2]
- other
- rash [2]
Drug interactions:
- increased incidence of dizziness when used with
- phenytoin, carbamazepine, lamotrigine, oxcarbazine [2]
Mechanism of action:
- blocks sodium channels
Notes: Manufacturer: UCB
Interactions
drug adverse effects of anticonvulsants
monitor with anticonvulsants
General
anticonvulsant
Database Correlations
PUBCHEM cid=219078
References
- Prescriber's Letter 16(2): 2009
New Drugs Approved by the FDA in 2008
Detail-Document#: 250213
(subscription needed) http://www.prescribersletter.com
- Medical Knowledge Self Assessment Program (MKSAP) 16, 17, 18
American College of Physicians, Philadelphia 2012, 2015, 2018
- George J
Your Brain on Cocoa; MS-Gut Link; Autism and Newborn Hearing
- News and commentary from the world of neurology and neuroscience.
MedPage Today November 24, 2020
https://www.medpagetoday.com/neurology/generalneurology/89868
- UCB Press Release. November 17, 2020
UCB-w VIMPAT (lacosamide) CV now approved by FDA in U.S. for
primary generalized tonic-clonic seizures and expanded pediatric use
for people living with epilepsy.
https://www.ucb.com/stories-media/Press-Releases/article/UCB-s-VIMPAT-lacosamide-CV-now-approved-by-FDA-in-U-S-for-primary-generalized-tonic-clonic-seizures-and-expanded-pediatric-use-for-people-living-with-epilepsy